Moomoo AI 已提取核心信息
Cardio Diagnostics Holdings, Inc., a company specializing in health diagnostics, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form S-3, filed on January 26, 2024, will not undergo review by the agency. The SEC's communication, dated January 30, 2024, was addressed to Dr. Meeshanthini Dogan, the Chief Executive Officer of Cardio Diagnostics Holdings. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. Daniel Crawford from the Division of Corporation Finance Office of Life Sciences is the contact person for any further inquiries.
Cardio Diagnostics Holdings, Inc., a company specializing in health diagnostics, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form S-3, filed on January 26, 2024, will not undergo review by the agency. The SEC's communication, dated January 30, 2024, was addressed to Dr. Meeshanthini Dogan, the Chief Executive Officer of Cardio Diagnostics Holdings. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. Daniel Crawford from the Division of Corporation Finance Office of Life Sciences is the contact person for any further inquiries.
美国证券交易委员会（SEC）已告知专门从事健康诊断的公司Cardio Diagnostics Holdings, Inc.，其于2024年1月26日提交的S-3表格注册声明将不接受该机构的审查。美国证券交易委员会于2024年1月30日发给了Cardio Diagnostics Holdings首席执行官Meeshanthini Dogan博士。美国证券交易委员会的信中还提到了与加快注册程序的请求有关的第460和461条。此外，美国证券交易委员会提醒该公司及其管理层，无论美国证券交易委员会的审查水平如何，他们都有责任确保披露的准确性和充分性。公司财务部生命科学办公室的丹尼尔·克劳福德是任何进一步询问的联系人。
美国证券交易委员会（SEC）已告知专门从事健康诊断的公司Cardio Diagnostics Holdings, Inc.，其于2024年1月26日提交的S-3表格注册声明将不接受该机构的审查。美国证券交易委员会于2024年1月30日发给了Cardio Diagnostics Holdings首席执行官Meeshanthini Dogan博士。美国证券交易委员会的信中还提到了与加快注册程序的请求有关的第460和461条。此外，美国证券交易委员会提醒该公司及其管理层，无论美国证券交易委员会的审查水平如何，他们都有责任确保披露的准确性和充分性。公司财务部生命科学办公室的丹尼尔·克劳福德是任何进一步询问的联系人。
有用
没用